News & Events

Dear partner,

As antibody and ADC pipelines expand globally, selecting the right CDMO partner is increasingly critical to development timelines, regulatory success, and long-term scalability.
At ChemExpress, our strength has been in complex small-molecule chemistry, particularly in linker and payload development. Today, we have strategically expanded our biologics&bioconjugates capabilities to build a truly integrated Antibody & ADC CDMO platform.

Q: How does ChemExpress position itself in antibody and ADC development?
A: ChemExpress operates as an integrated Antibody & ADC CDMO platform.
Our foundation lies in complex small-molecule chemistry, particularly linker-payload development. Building on this strength, we have established comprehensive biologics capabilities including antibody discovery, cell line development, GMP manufacturing, and ADC conjugation. This integrated structure enables coordinated development across antibody, payload-linker, and bioconjugation— minimizing technology transfer risk and improving development efficiency.

Q: What biologics capabilities does ChemExpress offer?
A: ChemExpress provides:
• Cell line development and cell bank construction
• Upstream and downstream process development
• GMP-compliant antibody DS and DP manufacturing
• Analytical method development and validation
Antibody production capacity ranges from 50L to 2000L, with expansion planned up to 8000L, supporting projects from preclinical to commercial stages.

Q: The project we want to work on is XDC. Where are the skills accumulated by ChemExpress over the years? Is it related to raw materials or registration?

A: ChemExpress has significant advantages in both materials and registration. We have a rich inventory of linkers and payloads, and continuously improve cost-effectiveness to ensure our products remain competitive. For the CMC of ADC small molecule part, we have supported customers in successfully completing over 70 IND projects, with 5 BLAs currently in progress. Additionally, our registration team has gained extensive experience in filing documentation in both English and Chinese, supporting dual submissions in the U.S. and China.

Q: What is ChemExpress’s strength in linker and payload development?
A: ChemExpress has long-standing expertise in complex and multi-chiral small molecules.
• Extensive linker-payload library (including Exatecan, MMAE series, Eribulin，PBD and other cytotoxins)
• 150+ Payloads in stock, 500+ Linkers in stock, 2000+ Linker CompoundSyntheses
• Advanced synthetic and process optimization capabilities
• High-throughput experimentation (HTE) platform
This capability ensures robust control over one of the most technically demanding components of ADC development.

Q: What are ChemExpress’s capabilities and capacity in antibody and ADC drug substance (DS) manufacturing?
A: ChemExpress offers integrated manufacturing capabilities for both antibody and ADC drug substances (DS), supporting projects across different development stages and scales.
For antibodies:
• Production scales: 50L, 200L, 500L, and 2000L
• 2,900L per production line
• Annual capacity: ~60 batches (120,000L total)
• Planned expansion capacity up to 8,000L
For ADCs:
• 50L–500L conjugation systems (disposable, glass, and stainless steel)
• 0.5–5 kg per batch
• Annual capacity: ~300 batches (1,500 kg throughput)
• 1 active conjugation line with expansion space reserved
This integrated platform enables a smooth transition from early development to scalable manufacturing.

Q: How does ChemExpress protect intellectual property?
A: ChemExpress is a pure service-oriented CDMO and does not independently develop innovative drugs.
• All intellectual property for client-designed molecules remains with the client
• Strict internal IP management and confidentiality systems are implemented
• A dedicated patent research team supports patent landscape analysis and risk evaluation

Advancing Complex ADC Programs Through Integration
In today’s ADC landscape, true differentiation lies in integration — not only chemistry strength or biologics capacity, but coordinated execution across modules. ChemExpress combines deep small-molecule expertise with expanding biologics capabilities to deliver a unified development pathway from discovery to commercial manufacturing. We welcome the opportunity to discuss your antibody or ADC program and explore tailored collaboration models.

For further technical discussion, please contact us at [email protected]。